Ferroptosis surveillance: Insights from in vivo contexts
Alec J Vaughan1,2, Mario Palma3, Jessalyn M Ubellacker3,4
1Department of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Abstract:
Ferroptosis has emerged over the past decade as a compelling therapeutic avenue for cancer, prompting intense interest in strategies that selectively induce or inhibit this form of cell death. Although substantial progress has been made in identifying genes that regulate ferroptosis sensitivity and in developing small-molecule modulators, it remains unclear which molecular targets offer the greatest therapeutic potential in specific tissues and contexts. Here, we highlight fundamental differences between in vitro and in vivo ferroptosis modulation, with emphasis on the integration of different techniques, mouse models, and how the tumor microenvironment shapes two major ferroptosis surveillance pathways: glutathione peroxidase 4 and ferroptosis suppressor protein 1. We propose that integrating in vivo biological constraints and microenvironmental complexity is essential for the rational design and successful translation of ferroptosis-targeted therapies.
Insights
Ferroptosis, a cell death pathway, shows promise for cancer therapy. Understanding differences between in vitro and in vivo studies is crucial for developing effective ferroptosis-targeted treatments.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Ferroptosis is a key cell death pathway with therapeutic potential in cancer treatment.
- Research has identified genes and small molecules regulating ferroptosis, but optimal targets remain unclear.
- Significant differences exist between in vitro and in vivo ferroptosis modulation.
Purpose of the Study:
- To highlight the differences between in vitro and in vivo ferroptosis modulation.
- To emphasize the role of the tumor microenvironment in ferroptosis.
- To propose a framework for designing effective ferroptosis-targeted therapies.
Main Methods:
- Review and integration of in vitro and in vivo studies on ferroptosis.
- Analysis of mouse models and tumor microenvironment influences.
- Focus on glutathione peroxidase 4 and ferroptosis suppressor protein 1 pathways.
Main Results:
- In vitro studies do not fully capture the complexity of ferroptosis in vivo.
- The tumor microenvironment significantly shapes ferroptosis surveillance pathways.
- Key pathways like GPX4 and FSP1 are modulated differently in vivo.
Conclusions:
- Integrating in vivo biological constraints is essential for ferroptosis therapy development.
- Understanding microenvironmental complexity is critical for successful translation of ferroptosis-targeted drugs.
- Future research should focus on in vivo validation of therapeutic strategies.
More Related Videos
11:12Nondestructive Monitoring of Degradable Scaffold-Based Tissue-Engineered Blood Vessel Development Using Optical Coherence Tomography
Published on: October 3, 2018
04:01Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
